INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 27, 2022...
Cancer
Sensus Healthcare Takes Order for 10 TransDermal Infusion Systems™ Supporting Hair Enhancement Centers Expansion Along with U.SK Under Skin’s Hair-Health Serum
BOCA RATON, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency
WORCESTER, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on...
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022...
Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers
CYNK-101 is an investigational genetically modified natural killer (NK) cell therapy designed to synergize with antibody therapeutics for difficult to...
MIMEDX Announces Formation of Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts
Scientific Advisory Board Adds Multi-disciplinary Clinical and Scientific Expertise to Support Acceleration of the Company’s mdHACM Placental Biologics Pipeline MARIETTA,...
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:...
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates
CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on...
Kura Oncology to Report Second Quarter 2022 Financial Results
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be...
vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer
HIGH POINT, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused...
Predictive Oncology Strengthens Business with Appointment of a Chief Scientific Officer and Consolidation and Expansion of its Research and Development Arm
Julia Kirshner, Ph.D. Predictive Oncology Appoints Julia Kirshner, Ph.D., as Chief Scientific OfficerEAGAN, Minn., July 26, 2022 (GLOBE NEWSWIRE) --...
SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)
AURELIO-04 will enroll up to 320 patients and test the combination in multiple solid tumor indicationsClinical collaborator, MSD (Merck &...
TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a...
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically...
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024
NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins,...
Sensus Healthcare to Host Second Quarter 2022 Financial Results and Business Update Conference Call on August 4, 2022
BOCA RATON, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2022 Financial Results
FLORHAM PARK, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
- At the highest dose level evaluated to date (Cohort 4, 0.128 mg/kg once daily), the mean change from baseline...
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from...